Related Experiment Videos
Increased Ca2+ influx into platelets induced by thromboxane A2 analog in patients with ischemic heart disease
N Kobayashi1, K Okumura, H Hashimoto
12nd Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Insights
Patients with ischemic heart disease (IHD) show enhanced platelet aggregation and calcium response to thromboxane A2 analogs. This suggests an abnormality in IHD platelet membranes affecting calcium permeability.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biochemistry
Background:
- Thromboxane A2 (TXA2) is a potent platelet activator involved in hemostasis and thrombosis.
- Platelet aggregation and intracellular calcium mobilization are critical events in thrombotic processes.
- Ischemic heart disease (IHD) is often associated with altered platelet reactivity.
Purpose of the Study:
- To compare platelet aggregation and intracellular free calcium concentrations ([Ca2+]i) in response to STA2, a TXA2 analog.
- To investigate differences between patients with IHD and healthy controls.
- To elucidate the role of extracellular and intracellular calcium in STA2-induced platelet activation in IHD.
Main Methods:
- Platelet aggregation assays were performed in the presence and absence of extracellular calcium.
- Intracellular free calcium concentrations ([Ca2+]i) were measured following STA2 stimulation.
- Comparisons were made between IHD patients with coronary stenosis and control subjects.
Main Results:
- STA2 induced a dose-dependent increase in platelet aggregation and [Ca2+]i in the presence of extracellular calcium.
- These responses were significantly higher in IHD patients compared to controls.
- No difference in [Ca2+]i increase was observed without extracellular calcium, indicating dependence on intracellular stores.
Conclusions:
- Thromboxane A2 enhances platelet aggregation by increasing intracellular calcium, primarily through promoting calcium influx.
- IHD patients exhibit an enhanced TXA2-mediated platelet response, suggesting increased calcium permeability.
- An abnormality in the platelet membrane of IHD patients may underlie this enhanced calcium influx and aggregation response.
Abstract:
We compared platelet aggregation and intracellular free calcium concentrations [( Ca2+]i) following stimulation with STA2, an analog of thromboxane A2 between patients with ischemic heart disease (IHD) showing significant stenosis in coronary angiograms and controls. In the presence of extracellular calcium, platelet aggregation and intracellular Ca2+ increase were enhanced by STA2 stimulation in a dose-dependent fashion and were higher in the IHD patients than in the controls. However, in the absence of extracellular calcium, no difference in intracellular Ca2+ increase was observed due to its total dependence on release from intracellular stores. These results suggest that thromboxane A2 increases platelet intracellular Ca2+-inducing aggregation, and this increase and aggregation, which is enhanced by thromboxane A2 in IHD patients, is due to promotion of Ca2+ influx by thromboxane A2. IHD patients appear to have an abnormality in the platelet membrane which may explain such thromboxane A2-dependent increased permeability to Ca2+.